Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VCN 01

Drug Profile

VCN 01

Alternative Names: VCN-01

Latest Information Update: 29 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VCN Biosciences
  • Developer AstraZeneca; Theriva Biologics; VCN Biosciences
  • Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Retinoblastoma; Adenocarcinoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
  • Phase I Brain cancer; Ovarian cancer
  • No development reported Solid tumours

Most Recent Events

  • 23 May 2024 VCN 01 receives Fast Track designation for Adenocarcinoma [IV,Infusion] (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA
  • 23 Apr 2024 Efficacy and adverse events data from a phase I trial in Retinoblastoma released by Theriva Biologics
  • 23 Apr 2024 Pharmacodynamics and safety data from preclinical studies in Pancreatic cancer released by Theriva Biologics
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top